Hypofractionated prostate radiotherapy: alternate delineation approach vs validated trial protocol
PO-1393
Abstract
Hypofractionated prostate radiotherapy: alternate delineation approach vs validated trial protocol
Authors: Iosif Strouthos1,2, Efstratios Karagiannis1,3, Paul Doolan4, George Antorkas4, Mary Peraticou1, Konstantinos Ferentinos1, Yiannis Roussakis4
1German Oncology Center, Radiation Oncology, Limassol, Cyprus; 2European university Cyprus, Medical School, Nicosia, Cyprus; 3European University Cyprus, Medical School, Nicosia, Cyprus; 4German Oncology Center, Medical Physics, Limassol, Cyprus
Show Affiliations
Hide Affiliations
Purpose or Objective
Two sets of radiotherapeutic plans were calculated, for a series of
patients treated for organ-confined prostate cancer with hypofractionated IGRT.
Head-to-head dosimetric comparison of a validated trial delineation protocol
against an alternative, simpler institutional approach was tested using dose-volume
histogram for planning target volume (PTV), followed by radiobiological
analysis of all cases plus “worst case” scenario.
Material and Methods
Twenty-one patients with locally confined prostate
adenocarcinoma treated initially with definitive, hypo-fractionated
radiotherapy adhering to the CHHiP protocol were retrospectively selected. All
patients were planned for volumetric modulated arc therapy (VMAT) on a
conventional linear accelerator. In addition to the validated trial PTV
definition, a set of “new” PTVs were defined for each case based on our
institutional simplified delineation protocol for normo-fractionated prostate
cancer. Adhering to ESTRO
guidelines, two different, institutional CTVs were utilised. CTVa, which included
the prostate and entire seminal vesicles and CTVb comprised of the prostate and
proximal seminal vesicles 14 mm from prostatic base. The newly derived PTVs were created through an
expansion of each of the delineated CTVs, 8 mm circumferentially plus a 6 mm expansion
posteriorly. New plans were calculated for each of the derived PTVs, delivering a
total physical dose of 60 Gy in 20 fractions, respecting and following the
planning parameters and dosimetric constraints expressed by the CHHiP trial
protocol. DVHs were used to evaluate the dose to the PTV and organs at risk
(OAR). Radiobiological evaluation was performed for all plans, using the
BioSuite software, calculating TCP for CTVb and NTCP for rectum and bladder,
utilizing a range of parameters and endpoints from the literature.
Results
All calculated
radiotherapeutic plans, regardless of CTV delineation and margin expansion, met
OAR DVH constraints, while at the same time achieving adequate target
coverage, as suggested by the CHHiP trial protocol. TCP calculation was >99%
for all plans and all cases. NTCP investigations revealed no statistically
significant differences.
Conclusion
Data based on dosimetric and
radiobiological comparisons demonstrate that our simpler institutional delineation
protocol is at least as effective in regard to PTV coverage, and as safe in
regard to OAR sparing, as the validated CHHiP trial PTV definition.